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Background: Antagonists of N-type voltage-gated calcium channels (VGCC), Cav2.2, can manage severe chronic
pain with intrathecal use and may be effective systemically. A series of novel ω-conotoxins that selectively inhibit
N-type VGCCs was isolated from Conus catus. In the present study, the potency and reversibility of ω-conotoxins
CVID, CVIE and CVIF to inhibit N-type calcium currents were investigated in mouse isolated dorsal root ganglion
(DRG) neurons. The systemic potency of each ω-conotoxin to reverse signs of mouse chronic inflammatory pain
was also compared.
Results: In DRG neurons, the rank order of potency to inhibit N-type calcium currents was CVIE > CVIF > CVID.
After subcutaneous administration, CVID and CVIE, but not CVIF, partially reversed impaired weight bearing in mice
injected with Freund’s complete adjuvant (CFA) three days prior to testing. No side-effects associated with systemic
administration of ω-conotoxins were observed.
Conclusions: The present study indicates a potential for CVID and CVIE to be developed as systemically active
analgesics with no accompanying neurological side-effects.
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Antagonists of the N-type voltage-gated calcium channel
(VGCC), Cav2.2, are potential therapeutics for the treat-
ment of pain. ω-Conotoxins are highly selective N-type
VGCC inhibitors isolated from the venom of cone snails
(genus Conus) [1]. After intrathecal administration, they
act to prevent conduction of nociceptive signals from the
peripheral to the central nervous system by inhibiting
neurotransmitter release from primary afferent nerve ter-
minals in the dorsal horn of the spinal cord. The first FDA
approved ω-conotoxin MVIIA (SNX-111, ziconotide or
Prialt) is administered intrathecally for management of
severe and chronic pain in patients who are intolerant or
refractory to the other treatments [2]. However, the thera-
peutic index of intrathecally administered Prialt is small,* Correspondence: mac.christie@sydney.edu.au
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reproduction in any medium, provided the orproducing severe side effects in many patients at thera-
peutic doses [3,4] and in animal models [5-7].
ω-Conotoxins are administered intrathecally to selectively
target Cav2.2 channels in the spinal cord. ω-Conotoxin
MVIIA is unsuitable for parenteral administration because
it produces serious side effects including cardiovascular
and autonomic dysfunction [6,8,9]. On the other hand, the
invasive surgery, high cost of implantation of pump, and
the risk of infection limit spinal administration [8,10].
More recent studies have suggested that other ω-
conotoxins, such as CVID, can produce some pain relief
following parenteral administration with a wider thera-
peutic window than MVIIA [8]. Intravenous injection of
ω-conotoxin CVID produced dose-dependent antihyper-
algesic effects without serious cardiovascular side effects
[8]. The mechanism responsible for the superior thera-
peutic index of CVID versus GVIA and MVIIA is not yet
known although it could be due to its higher selectivity
for N-type VGCCs over the P/Q-type (Cav2.1) [5,6,11,12].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CVID with Cav2.2 [12], different biodistribution or metab-
olism may also be responsible.
We recently identified a novel series of ω-conotoxins
from Conus catus [12]. Importantly, CVIE and CVIF po-
tently and reversibly inhibited Cav2.2 channel currents
in a voltage-dependent manner and reversibly inhibited
excitatory monosynaptic transmission in the dorsal horn
of the spinal cord. In contrast, CVID, MVIIA and GVIA
produced irreversible inhibition [13,14]. CVIE and CVIF
produced similar but reversible inhibition of mechanical
allodynia in a nerve-injured rat model after intrathecal
administration [12]. The combination of high potency,
selectivity and reversibility of Cav2.2 block might con-
tribute to improved efficacy or a wider therapeutic index
of ω-conotoxins after intrathecal and potentially paren-
teral administration.
In the present study, we investigated the potency and
reversibility of CVIE and CVIF in isolated sensory neu-
rons dissociated from mouse dorsal root ganglion neurons


























Figure 1 Inhibition of VGCCs in DRG neurons by ω-conotoxins. A. Cur
by 300 nM CVID. Inset, representative recording of ICa, with the current trac
HVA ICa by specific blockers for different calcium channel subtypes, i.e. CVID
for ICa resistant (res.) to all other blockers . Inset, proportions of the differen
C. Representative recordings of ICa showing block by ω-conotoxins CVIE anconotoxins produced greater inhibition of inflammatory
pain-related behaviours when compared to CVID in mice.
Results
Inhibition of whole-cell ICa by ω-conotoxins in isolated
DRG neurons
Robust inhibition of total ICa was seen with CVID
(Figure 1A). As shown in Figure 1B, CVID inhibited about
40% of the total ICa, ω-agatoxin IVA, approximately
30%, nimodipine 5%, and the residual current was
blocked by SNX-482 and CdCl2. As previously reported
in mouse trigeminal ganglion neurons [15] using other
N-type VGCC antagonists, N-type current inhibited by
each ω-conotoxin contributed to approximately 50% of the
total ICa (Figure 1C). As shown in Figure 1B, Agatoxin
IVA inhibited approximately 30% of the total ICa re-
presenting the contribution of P/Q-type channels (Cav2.1),
nimodipine inhibited 4% representing the L-type, the
blocker of R-type channels (Cav2.3), SNX-482, was without
effect and residual ICa was blocked by CdCl2 (50 μM). The


























































rent–voltage (I-V) curve showing the block of high-voltage activated ICa
e following block by CVID shown in green. B. Time-plot of inhibition of
for N-, ω-agatoxin IVA for P/Q-, nimodipine for L-, SNX-482 and CdCl2
t subtypes shown as percentages present in mouse DRG neurons.
d CVIF. D. Concentration-response curves for each ω-conotoxin.
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to SNX-482 [16], as well as other Cav currents.
When the concentration-response curves were plotted
(Figure 1D), CVIE was found to be the most potent at
ICa inhibition, more than ten-fold compared to CVID
(P < 0.001 using two-way ANOVA with Bonferroni’s
post-test), which was the least potent. Inhibition param-
eters are shown in Table 1.
We then examined the reversibility of ICa inhibition by
the different conotoxins. As shown in Figure 2A, no re-
covery was seen from CVID and CVIE block even after
30 min of recording. Figure 2B shows the summary of
recovery from the different conotoxins over 10 min.
CVID and CVIE were completely irreversible and CVIF
was partially reversible with recovery of up to 24% (see
Table 1).
Development of hyper-responsiveness: incapacitance
versus automated von Frey
As shown in Figure 3, automated von Frey (Figure 3A)
and incapacitance (Figure 3B) testing revealed hyper-
responsiveness of the inflamed hindpaw for at least 4 days
following injection of CFA. In order to determine if
incapacitance and automated von Frey testing produced
similar outcomes, responses to von Frey filaments were
correlated in groups of mice injected with CFA (n = 14) or
saline (n = 14), 4 days After injection. Responses were
highly correlated (R2 = 0.94, P < 0.001). In a pilot study
of 4 animals, 2 mg/kg CVID was injected 3 days after
induction of inflammation and hyper-responsiveness was
assessed using both measures. Since both measures
appeared to be sensitive to subcutaneous injection of
CVID (Figure 3C), we chose the simpler incapacitance
measure for the remainder of the study.
Time- and dose response relationships for ω-conotoxins
in vivo
CVID
The time-response curves for each dose of CVID and
vehicle are shown in Figure 4A. CVID produced reversal
of incapacitance, with significant reversal at the peak
time of action (2 h) for both 0.2 and 2.0 mg/kg doses.Table 1 Inhibition parameters of the three ω-conotoxins on IC
Peptide CVID
Maximal Inhibition of ICa (% of total) 52 ± 2
Log [IC50] −7.12 ± 0
Recovery from block (% of inhibition, 10 min) −1 ± 5
Peak inhibition vs. recovery at 10 min (t-test) P = 0.3
No significant difference was observed in the maximal inhibition by any of the pep
responses of the three peptides were tested using two-way ANOVA (P < 0.0001) and
than that of CVIE and CVIF (P < 0.001 for both comparisons), but no difference was
response relationships were not significantly different from 1. Recovery from block
inhibition by CVIF (P < 0.05).The response to CVID appeared to reach a ceiling at
0.2 mg/kg. Overall significance of AUC data was also
achieved for 0.2 and 2.0 mg/kg (Figure 4D).
CVIE
The time-response curves for each dose of CVIE and ve-
hicle are shown in Figure 4B. CVIE produced significant
reversal of incapacitance at the points indicated. For CVIE,
2.0 mg/kg was clearly the most effective dose. It should be
noted that unlike CVID, CVIE did not appear to reach a
ceiling at the highest dose tested. Overall significance was
achieved for AUC data at 2.0 mg/kg. Although CVIE
appeared to produce greater maximal reversal of inca-
pacitance than CVID, two factor ANOVA of AUC for
CVID and CVIE dose–response data did not reveal any
significant differences.
CVIF
The time-response curves for each dose of CVIF and ve-
hicle are shown in Figure 4C. Although there was a trend
for reversal of incapacitance at the highest dose, CVIF did
not produce significant reversal of incapacitance.
Dose–response relationships
Figure 4D shows the AUC calculated for each animal with
the corresponding pre-injection baseline subtracted. One-
way ANOVA was used to test the difference between the
dose and vehicle for each dose of each drug, and the sig-
nificance is indicated in Figure 4D. To test whether there
was a significant potency difference among peptides, a
two-way ANOVA with all possible post-hoc contrasts
using Bonferroni correction (excluding vehicle). CVIE
was significantly more potent than CVIF at 2.0 mg/kg
(P < 0.01) but not CVID at any dose.
Side effects
None of the animals exposed systemically to ω-conotoxins
displayed any of the typical side effects usually observed
after intrathecal administration [5-7]. No other overt signs
were noted in animals injected with ω-conotoxins. Three
vehicle injected animals displayed tail shaking and were
not included in the analysis because their incapacitancea recorded from isolated DRG neurons
CVIE CVIF
45 ± 4 47 ± 6
.04 −8.22 ± 0.03 −7.85 ± 0.03
0 ± 3 24 ± 10
P = 0.2 P < 0.05
tides (P = 0.52 with one-way ANOVA). Differences between the concentration-
followed up with Bonferroni’s post-test. The IC50 of CVID was significantly less
found between CVIE and CVIF (P > 0.05). Hill slopes of all three concentration-
was tested using paired t-test, and significant recovery was observed only from
A B



























Figure 2 Reversibility of inhibition of VGCCs by ω-conotoxins. A. Representative time plots from two neurons showing block of ICa
(normalised to maximum ICa) by CVID and CVIE, followed by washout. Note that no recovery was observed up to 30 minutes of washout of the
peptides. B. Summary timeplots showing recovery from ICa block following washout of the different conopeptides at 10 minutes. Partial recovery
was seen following washout of CVIF and no recovery was observed after application of CVID and CVIE.
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conotoxins produce any effects on motor coordination or
performance, maximal doses (2 mg/kg) of each conotoxin
on rotarod performance and grip strength was tested at
the time of maximal effect (2 h) in a separate cohort of
mice. As shown in Table 2, none of the conotoxins pro-
duced a significant effect on motor coordination or grip
strength.
Discussion
ω-Conotoxins selective for N-type calcium channel are
an established class of therapeutics for the treatment of
chronic pain and there is evidence that they have some
efficacy with systemic administration. In this study we
characterized the effects of two novel ω-conotoxins,
CVIE and CVIF. All conotoxins selectively inhibited N-
type calcium channels in mouse DRG neurons, consist-
ent with a previous report in rat [12]. As expected, the
maximal inhibition by these conotoxins was very similar
to that of CVID, which also has high selectivity for N-
type calcium channels [17]. The contribution of the
other types of calcium channels was also determined
using specific blockers for P/Q-type (ω-agatoxin IVA)
and L-type (nimodipine), as well as CdCl2 to block the
residual resistant current. The lack of effect of the R-
type inhibitor, SNX-482, suggests that the Cd2+-sensitive
residual current may be mediated, in part, by a variant
of Cav2.3 that is insensitive to this peptide [16]. Other
channels may underlie this resistant current because a
residual current is also present in Cav2.3 knock-out mice
[18]. These results confirm that N-type calcium channels
contribute to approximately 50% of the total ICa. We
also found that CVIE was the most potent of the
conotoxins examined, with a more than ten-fold greater
IC50 than that of CVID, which was the least potent.
A potential determinant of the therapeutic window of
ω-conotoxins is their reversibility because a high side-effect profile is seen with the irreversible ω-conotoxins,
including MVIIA and CVID [19]. Therefore, we were
interested in the reversibility of these ω-conotoxins
in vitro. At −80 mV, CVID and CVIE were completely
irreversible and CVIF was partially reversible, consistent
with previous reports [12]. We did not observe any side
effects following administration of all three peptides, in-
dicating a potential for these conotoxins to be adminis-
tered systemically. This also indicated that in our study,
irreversibility in vitro did not produce behavioural side-
effects in vivo following peripheral administration. The
absence of side-effects in this study is also consistent
with the report from Kolosov et al. [8] who reported
much lower side-effect scores for intravenously adminis-
tered CVID compared to MVIIA in rat. None of the ω-
conotoxins produced obvious side effects or significant
effects on motor coordination and grip strength but it
will be important in future studies to determine the rela-
tive ability of CVID and CVIE to produce hypotension
as this is a potential dose-limiting side effect in humans.
The lack of neuronal side-effects following systemic ad-
ministration of ω-conotoxins could be due to a differen-
tial expression of auxiliary subunits associated with the
N-type calcium channel in sensory and autonomic neu-
rons. It has been shown previously that recovery from
CVIE and CVIF block is much greater in the presence of
β2a subunits compared to β3 subunits [12]. Additionally,
the presence of α2δ subunits significantly reduces the af-
finity of CVID for N-type calcium channels, while de-
creasing recovery from CVID block [20]. Bioavailability
and distribution may also play a role, however, less is
known about those factors at present.
When we compared the in vivo and in vitro
concentration-responses of these peptides, our findings
were quite unexpected. CVID and CVIE were most ef-
fective at reversal of pain, with the former reaching a
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Figure 3 CFA-induced mechanical thresholds using von Frey
filaments and incapacitance. A. Time to withdrawal measured
using automated von Frey testing showed that both paws showed
equal latency before CFA injection. Following injection, the time to
withdrawal was significantly reduced in the injected paw compared
to the contralateral paw, and the effect remained up to four days
following CFA injection. B. Incapacitance testing was used to
measure the ratio of weight-bearing between the two paws. This
ratio went from 1 before CFA injection, indicating equal weight-
bearing, to close to 0.5 following injection, indicating preference of
the contralateral paw. This effect was measurable up to four days
following CFA injection. C. Comparison of automated von Frey and
incapacitance testing showed similar development of allodynia,
which could be partially reversed by administration of CVID. No
differences were seen between the two methods, therefore
incapacitance testing was used in subsequent experiments in the
interest of time.
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nificantly greater than CVID. This indicates that in vivo,
CVID is more potent than CVIE, contrary to the results
in vitro. It is possible that reversibility of the peptides
would increase potency in vivo. However, we found no
significant differences in reversibility between CVID and
CVIE, suggesting that this explanation would only be
plausible if reversibility differed greatly in peripheral tar-
get tissues other than DRG neurons. Distribution and
bioavailability could be significant in determining the ac-
tions of CVID and CVIE in vivo, which is beyond the
scope of the present study.
Conclusions
The major finding of this study was that systemically ad-
ministered ω-conotoxins CVID and CVIE reverse signs
of inflammatory pain. Importantly, this was not accom-
panied by side-effects such as motor deficits or sedation.
The in vitro potency and reversibility of all ω-conotoxins
examined were not predictive of efficacy or presence of
side-effects in vivo. This underscores the need for future
studies to investigate factors such as bioavailability, dis-
tribution and tissue-specific effects of these peptides.
Methods
Male C57 Bl6 mice (20–25 g, n = 177 for in vivo experi-
ments, and 6–10 week-old, n = 20 for in vitro DRG
neuron recordings) were used in this study. Animals
were housed in groups of four to six with environmental
enrichment on a 12 h/12 h light–dark cycle at 22 ± 2°C,
with ad libitum access to food and water. All experi-
ments were conducted according to protocols approved
by the Animals Ethics Committee of the University of
Sydney, Sydney, NSW, Australia which complies with the
National Health and Medical Research Council ‘Australian
code of practice for the care and use of animals for scien-
tific purposes’.
Isolated DRG neuron preparation
DRG neurons were isolated from adult mice (6–10 weeks)
as previously described [21]. Mice were anaesthetized with
isofluorane (4% in air) and decapitated. Dorsal root ganglia
(spinal levels L3 – L5) were removed and placed in ice-
cold Hepes-buffered saline (HBS) containing (mm): NaCl,
154; KCl, 2.5; CaCl2, 2.5; MgCl2, 1.5; Hepes, 10; glucose,
10; pH 7.4 (NaOH), 330 ± 5 mosmol l−1. Ganglia were cut
up with iridectomy scissors and incubated at 37°C for
15 min in oxygenated HBS containing 3 mg ml−1 collage-
nase and for 25 min in oxygenated HBS containing
1 mg ml−1 papain. The digestion was terminated with
addition of HBS containing 1 mg ml−1 bovine serum
albumin and 1 mg ml−1 trypsin inhibitor. Ganglia were
washed free of enzyme and enzyme inhibitors with room-
















































































Figure 4 Time-course and dose-dependence of reversal of allodynia by systemic ω-conotoxins. A-C. Systemic ω-conotoxins partially
reverse CFA-induced incapacitance. Effects of CVID, CVIE and CVIF respectively at doses of 0.02, 0.2 and 2 mg/kg on allodynia following CFA
injection. D. Area under the curve measurements corrected for baseline with vehicle show that CVID and CVIE were the most effective at
reversing mechanical alldoynia, with CVID reaching a ceiling effect at 0.2 mg/kg which was not seen with CVIE.
Sadeghi et al. Molecular Pain 2013, 9:51 Page 6 of 9
http://www.molecularpain.com/content/9/1/51through decreasing bore, silanized Pasteur pipettes with
fire-polished tips. The cells were plated onto plastic cul-
ture dishes and kept at room temperature in HBS. Cells
remained viable for up to 10 h after dissociation.
Electrophysiological recording from DRG neurons
Ionic currents from mouse DRG neurons were recorded
in the whole-cell configuration of the patch-clamp method
at room temperature (22 – 24°C) as previously described
[21]. Dishes were continually superfused with HBS. For
isolating ICa, the extracellular solution contained (mM):
140 tetraethylammonium chloride, 2.5 CsCl, 2.5 CaCl2,
10 Hepes, 1 MgCl2, 10 glucose; pH 7.2 (with CsOH),Table 2 Effects of the three ω-conotoxins on motor coordinat
test using a grip strength meter
Treatment/test Rotarod performance
Time to fall (s) End rate (
Vehicle (n = 9) 39 ± 4.2 18 ± 1.4
CVID (n = 7) 40 ± 4.1 18 ± 1.4
CVIE (n = 7) 36 ± 4.1 17 ± 1.4
CVIF (n = 7) 36 ± 3.0 17 ± 1.0
All ω-conotoxins were tested in naïve mice at the maximal analgesic dose (2 mg/kg
produced any significant effect on ability of mice to perform on the rotarod or mai330 ± 5 mosmol l−1. The intracellular pipette solution
contained (mM): 120 CsCl, 10 Hepes, 10 EGTA, 2 CaCl2,
5 MgATP, 0.2 Na2GTP, 5 NaCl; pH 7.3 (CsOH), 285 ±
5 mosmol L−1. Recordings were made using an EPC-9
patch-clamp amplifier and corresponding PULSE software
from HEKA Electronik (Lambrecht/Pfalz, Germany). Cur-
rents were sampled at 20 – 50 kHz and recorded on hard
disk for later analysis. Patch pipettes were pulled from
borosilicate glass (AM Systems, Everett, WA, USA). The
pipette input resistance ranged between 1.5 and 2.5 MΩ.
The capacitance of individual cells was estimated by
PULSE software by fitting an exponential to current re-
sponses to small rectangular voltage pulses and rangedion tested on an accelerating rotarod and grip strength
Grip strength
rpm) Peak tension (g) Tension/weight
130 ± 5.5 5.8 ± 0.3
121 ± 5.7 5.7 ± 0.3
121 ± 6.9 5.5 ± 0.3
121 ± 7.7 5.4 ± 0.4
, s.c.) at the time of maximal analgesic effect (2 h). None of the ω-conotoxins
ntain grip strength (each parameter tested by one-factor ANOVA; all P > 0.6).
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and 10 MΩ. Series resistance compensation of between
70% and 80% was used in all experiments. Capacitative
transients were compensated automatically using a built-
in procedure of the HEKA amplifier. Leak current was
subtracted online using a P/8 protocol. Liquid junction
potential of 4 mV was not corrected for.
Peak high voltage-activated (HVA) ICa in each cell was
determined by stepping the membrane potential from a
holding potential of −90 mV to between −60 and 30 mV,
for 10 ms, in 10 mV increments. Following this proced-
ure, the test current was evoked (−80 to 0 mV) every
30 s and monitored for current stability before drugs
were applied. Cells were exposed to the conopeptides at
increasing concentrations via a series of flow pipes posi-
tioned above the cells. All conopeptides were synthe-
sized and analyzed as described previously [12]. The
inhibition by conopeptides was quantified by measuring
the current isochronically from the peak of the control
current in the presence and absence of the drug.
Induction of inflammatory pain
Mice were injected subcutaneously in the plantar surface
of the left hindpaw with 50 μL undiluted Complete
Freund’s Adjuvant (CFA) (Sigma-Aldrich, USA) under
brief isoflurane anaesthesia (4% in air) using a 50 μL
Hamilton syringe.
Hindpaw weight bearing (incapacitance) and automated
von Frey testing
Measurement of hindpaw weight bearing in mice pro-
vides a robust measure of severity of mechanical hyper-
algesia following hindpaw inflammation and is sensitive
to antinociceptive drugs [22]. Weight bearing was mea-
sured using a Linton incapacitance tester (Linton Instru-
ments, UK). At each time point, five measurements were
collected over 3–5 minutes, averaged and the ratio of
load on left/right paw recorded as a single data point.
Data points not involving clear contact of both paws
with the test plates were not collected or analysed.
Highly variable data were observed when incapacitance
ratios when post-CFA ratios were much greater than 0.6.
This suggested inadequate development of allodynia un-
less post-CFA ratios were less than 0.65. All animals
exhibiting a post-CFA ratio of greater than 0.64 were
therefore not tested further. In preliminary experiments,
allodynia was also measured using an automated von
Frey threshold tester (Dynamic Plantar Anesthesiometer,
Ugo Basile). In this test mice were acclimatized to a
raised, wire mesh floored chamber and the test was
performed 5 times on each hindpaw over a period of ap-
proximately 5–8 minutes. The ratio of latency is calcu-
lated for each measurement and expressed as a ratio of
left/right paw.Drug injection
Three days after induction of inflammation, each peptide
injection was prepared by an independent researcher in
sterile, pyrogen free isotonic saline (0.9%) vehicle and
coded. A baseline measure of incapactiance was recorded
immediately before drug injection. Immediately after base-
line measurement, drugs or vehicle were injected by the
observer who was blinded to the treatment subcutane-
ously near the scruff of the neck in a volume of 10 ml/kg.
Each syringe used contained no more than 2 coded doses
(sometimes 1) and most daily experiments included 8 ani-
mals. Incapacitance scores were then recorded for each
animal at 1, 2, 4, and 6 hours after injection.
Side effect scores
ω-Conotoxins produce characteristic side effect signs in
rodents after intrathecal injection [5-7]. These include
tail writhing, paw tremor and whole body shakes. All an-
imals were observed individually for these signs and any
other observable signs such as obvious sedation or
hyperactivity, any form of shaking, display of discomfort
including pilorection and escape behaviour. These were
scored for each animal in an observation chamber for a
period of 5 minutes at each time point.
Motor side effects
Potential motor side effects were assessed in male C57Bl/
6j mice (n = 30, 20–25 g). Animals were tested 2 hours
after injection of either 2 mg/kg (0.2 mL, s.c.) of ω-
conotoxin (CVID, CVIE, or CVIF) or saline. The accelerat-
ing rotarod (IITC Life Sciences, Series 8) rotational speed
was increased from 5 to 45 rpm over 2 minutes. Time to
fall (s) and peak rotational speed (rpm) were recorded,
with at least 5 min inter-trial interval allowed. Mice were
trained for 5 trials per day for the two days preceding test-
ing. On testing day, 3 trials were recorded and averaged
for each mouse Forepaw grip strength was determined
using a grip strength meter (DFIS-2 series digital force
gague, Columbus Instruments, Columbus, Ohio). The
amount of force required to pull the mouse from a pull
bar was recorded. Each mouse was tested 5 times, with
1 min inter-trial interval. The average peak tension (g),
and tension normalised to body weight were compared.
Data analysis
For electrophysiological analyses, all data are expressed
as the mean ± SEM unless otherwise indicated. Concen-
tration–response data were pooled for each group and
fitted to a logistic equation with a minimum constrained
to zero using the software package GraphPad Prism v. 5.
Where noted, significant differences between means
were tested using paired or unpaired two-tailed Student’s
t tests, or when more than two groups were included,
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ences between frequency data were tested using χ2 tests.
In behavioural experiments, after breaking the code
for each drug treatment, data were collated and analysed
using GraphPad Prism version 5. Raw incapacitance data
for each peptide was analyzed by two-way ANOVA with
repeated measures and, when significant, Bonferroni’s
post-hoc tests for planned contrasts between vehicle and
drug effects. To compare dose–response data and com-
pare each group directly with vehicle controls, area
under the time response curve was calculated for each
animal at each dose of each peptide (and vehicle). One
way ANOVA (ungrouped data) for each peptide was
performed using the vehicle control group follow by
Dunnett’s post-hoc test for differences from the vehicle
group. The area under the curve (AUC) for dose–re-
sponse data for all peptide were also compared by two
factor ANOVA (ungrouped data) to test whether there
were potency significant potency differences. Significant
effects are shown throughout as * = P < 0.05, ** = P < 0.01,
*** = P < 0.001.Drugs and chemicals
Bovine serum albumin (BSA), trypsin inhibitor (chicken
egg white ovomucoid, Type II-O) and CdCl2 were from
Sigma-Aldrich. Papain and collagenase were from
Worthington Biochemical Corporation (Freehold, NJ,
USA). ω-Conotoxins were provided by R.J. Lewis, Insti-
tute of Molecular Biology, University of Queensland.
Nimodipine was fromTocris Cookson (Bristol, UK). ω-
Agatoxin IVA and SNX-482 were from Peptide Insti-
tute, Inc. (Osaka, Japan).
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